![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 7, 4848-4857, February 18, 2000
§,
¶,
,
, and
**
From the
Institut de Biologie, Laboratoire Infections
Rétrovirales et Signalisation Cellulaire,
CRBM-CNRS UPR 1086, 4 Boulevard Henri IV,
34060 Montpellier, France
| |
ABSTRACT |
|---|
|
|
|---|
Regulation of viral genome expression is the
result of complex cooperation between viral proteins and host cell
factors. We report here the characterization of a novel cellular factor
sharing homology with the specific cysteine-rich C-terminal domain of the basic helix-loop-helix repressor protein I-mfa. The synthesis of
this new factor, called HIC for Human I-mfa
domain-Containing protein, is controlled at the
translational level by two different codons, an ATG and an upstream
non-ATG translational initiator, allowing the production of two protein
isoforms, p32 and p40, respectively. We show that the HIC protein
isoforms present different subcellular localizations, p32 being mainly
distributed throughout the cytoplasm, whereas p40 is targeted to the
nucleolus. Moreover, in trying to understand the function of HIC, we
have found that both isoforms stimulate in T-cells the expression of a
luciferase reporter gene driven by the human T-cell leukemia virus type
I-long terminal repeat in the presence of the viral transactivator Tax. We demonstrate by mutagenesis that the I-mfa-like domain of HIC is
involved in this regulation. Finally, we also show that HIC is able to
down-regulate the luciferase expression from the human immunodeficiency
virus type 1-long terminal repeat induced by the viral transactivator
Tat. From these results, we propose that HIC and I-mfa represent two
members of a new family of proteins regulating gene expression and
characterized by a particular cysteine-rich C-terminal domain.
Human T-cell leukemia virus type I
(HTLV-I)1 and human
immunodeficiency virus type 1 (HIV-1) are both human retroviruses that infect in vivo CD4+ T lymphocytes. However,
these infections lead to two extremely different diseases. Infection
with HTLV-I results in dysregulation of T-cell proliferation, sometimes
causing the development of adult T-cell leukemia. By contrast,
infection with HIV-1 causes the loss of T-cells, resulting in systemic
immunosuppression and development of AIDS. Characterization of
molecular mechanisms involved in the interactions between viral and
cellular components contributes to understanding why HTLV-I and HIV-1
have different effects on the infected T-cell growth. For instance, the
transcriptional regulators used by T-cells to control cell function are
used differently by HTLV-I and HIV-1 to regulate expression of their
genome. Both retroviruses utilize the cellular RNA polymerase II to
transcribe their genome (1-4) but also code for their own regulatory
proteins that regulate the transcription of viral and cellular genes.
Thus, HIV-1 Tat protein is able to activate transcription from the
viral long terminal repeat (LTR) promoter (5-7) by interacting with the transactivation responsive element located at the 5' end of viral
mRNAs (8-10) and then with general transcription factors (for
reviews see Refs. 11 and 12). By contrast, HTLV-I Tax protein is unable
to bind specifically to nucleic acids (13-15). To stimulate
transcription from LTR promoter, Tax is recruited by interaction with
the activating transcription factors/CRE-binding proteins (ATF/CREB)
(16-20) that bind to the three imperfect 21-bp cAMP-responsive
elements located in the U3 of the LTR (21-25). Then, Tax could
stimulate transcription by recruiting the coactivator CREB-binding
protein (CBP) (26-28) and by interacting with basal transcription
factors (29-31).
Basic helix-loop-helix (bHLH) proteins regulate cell determination and
differentiation during embryogenesis (for reviews see Refs. 32 and 33).
For example, the cell fate of skeletal muscle precursors is regulated
by the MyoD subfamily of bHLH factors including
MyoD, Myf5, myogenin, and MRF4 (33,
34). bHLH proteins are also involved in lineage commitment and
differentiation as Mash2 and Hand1, which play a role in trophoblast
development (35-37). The activity of bHLH factors is regulated to
achieve the coordinated expression of genes during development.
Recently, a novel myogenic repressor has been identified called I-mfa
for Inhibitor of MyoD family (38, 39). I-mfa is generated
with two additional proteins, I-mfb and I-mfc, by alternative splicing (38). The three I-mf proteins share a common N-terminal region, but
each has a different C terminus, the I-mfa-specific C terminus being
characterized by a high content of cysteines. I-mfa is distributed mainly throughout the cytoplasm, although it is also detectable in the
nucleus (38). I-mfa inhibits myogenic bHLH proteins by retaining them
in the cytoplasm and by interfering with their DNA binding activity in
the nucleus (38). I-mfa is also able to inhibit the transactivation
activity of Mash2 and plays an important role in trophoblast and
chondrogenic differentiation (39). On the other hand, the functions of
I-mfb and I-mfc still remain unclear.
In this study, we report the isolation and characterization of a human
cDNA clone encoding a novel protein, which exists in two isoforms
differing by the presence or absence of a basic amino acid-rich
N-terminal domain and by their localization in the cell. Both isoforms
contain a common C terminus sharing homology with the specific
C-terminal domain of I-mfa. We show that this new factor, called HIC
for human I-mfa domain-containing
protein, stimulates the expression of a luciferase reporter gene driven by the HTLV-I LTR in the presence of Tax. By using mutagenesis, we
demonstrate that the I-mfa-like domain of HIC is required to stimulate
luciferase expression. Finally, we also show that HIC is able to
down-regulate expression from HIV-1 LTR in the presence of Tat. From
these results, we propose that HIC and I-mfa represent a new family of
proteins regulating gene expression and are characterized by the
presence of a specific cysteine-rich C-terminal domain. Our results
also suggest that HIC could differently regulate expression of HTLV-I
and HIV-1 genomes.
Molecular Cloning of a 4,152-bp Full-length HIC
cDNA--
HIC cDNA clones were first isolated from a MT-2
cDNA library by the yeast two-hybrid approach. MT-2 cDNA fused
to the GAL4 activation domain of the pGAD10 vector (20) was screened by using the cytoplasmic tail of CD4 as a bait fused to the LEXA DNA
binding domain of the pBTM116 vector. The two-hybrid screen was
performed as already described (20) with the Saccharomyces cerevisiae L40 reporter strain.
The multiple tissue Northern blot and the human spleen cDNA library
cloned into In Vitro Transcription and Translation--
All the different
HIC cDNAs cloned into pSPORT 1 (Life Technologies, Inc.) were
transcribed and translated in the presence of
[35S]methionine and [35S]cysteine by using
the TNT T7 coupled transcription-translation reticulocyte lysate system
of Promega. Translation products were analyzed by SDS-PAGE and
autoradiography. pHIC-1 corresponds to an
SalI-SpeI fragment that contains the first 1532 bp of the HIC cDNA subcloned into pSPORT 1. The 5'-deleted
plasmids, pHIC-2, -3, -4, and -5, were either constructed by
restriction endonuclease digestion and religation of pHIC-1 or
generated by PCR amplification on pHIC-1 and subcloned into pSPORT 1. Templates where CTG or GTG were mutated were also generated by PCR
amplification; CTG at position 246 was transformed into ATG
(pHIC-I-atg) or CGG (pHIC-I-cgg), GTG at position 264 into ATG
(pHIC-II-atg) or CGG (pHIC-II-cgg), and CTG at position 321 into ATG
(pHIC-III-atg).
Expression of HIC p32 and p40 Tagged with Either GFP or myc
Epitope in COS7 Cells--
To express HIC p32 and p40 with a GFP or
myc tag, the complete coding sequences of both proteins were
subcloned into the vectors pEGFP-N1 (CLONTECH),
pEGFP-C1 (CLONTECH), and pcDNA3.1( Transfections and Luciferase Assays--
The coding sequences of
p32 and p40 were cloned into a eukaryotic expression vector,
pcDNA3.1/His (Invitrogen). The plasmid pcDNA3.1/His-HIC Immunoprecipitation and Western Blot Assays--
Protein
extracts were electrophoresed onto SDS-10% polyacrylamide gel
(SDS-10% PAGE) and blotted to polyvinylidene difluoride membranes
(Millipore). The blot was then incubated overnight at 4 °C with a
blocking solution (phosphate-buffered saline containing 5% milk) prior
to addition of antiserum. After 2 h at 20 °C, the blot was
washed three times with 0.5% phosphate-buffered saline/Tween 20 and
incubated for 2 h with goat anti-mouse or anti-rabbit
immunoglobulin-peroxidase conjugate (Immunotech, Marseille, France).
After three washes, the membrane was incubated with enhanced
chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech). The
membrane was then exposed for 0.5 to 5 min to hyperfilms-ECL (Amersham
Pharmacia Biotech). The anti-Xpress serum was purchased from Invitrogen
and recognizes the tag found in the Xpress leader peptide in the vector
pcDNA3.1/His. The anti-HIC serum was obtained by immunizing rabbits
with purified His6-tagged HIC polypeptide corresponding to
the first 163 amino acids of p32. HIC cDNA was cloned into the
bacterial expression vector pQE-30 (Qiagen). The N-terminal
His6-tagged protein was purified as described by the
manufacturer. Immunoprecipitation assay was carried out as described
previously (43).
Isolation of HIC cDNA, Which Encodes a Protein Sharing Homology
with the Specific C-terminal Domain of I-mfa--
Two cDNA clones
coding, respectively, for the last 60 and 153 C-terminal amino acids of
a novel protein were isolated from an HTLV-I-infected T-cell line
cDNA library (20). As the predicted polypeptide presented
homologies with the specific C-terminal domain of I-mfa, a cellular
factor known to be a bHLH repressor, we decided to characterize further
this novel protein. At first, the tissue distribution of the mRNA
coding for this novel HIC protein was analyzed. All the tested lymphoid
organs (spleen, thymus, and peripheral blood leukocytes) expressed an
mRNA of about 4.4 kb (Fig. 1). This
mRNA is not specific to lymphoid tissues since it is expressed in
prostate, uterus, and small intestine. Finally, it is almost absent in
testis and colon. From these observations, we decided to screen a human
spleen cDNA library cloned into Mapping of the Translation Initiation Sites--
The full-length
HIC cDNA contains an open reading frame encoding a polypeptide of
246 amino acids if the ATG at position 591 is the initiation codon
(Fig. 2). We examined the proteins
synthesized in a cell-free system with a cDNA containing the first
1532 nucleotides of HIC sequence (the stop codon TAA is at position
1329; see Fig. 2). SDS-PAGE of the translational products effectively
revealed a protein of 32 kDa, p32, but also an unexpected product of 40 kDa, p40 (Fig. 3a, lane
pHIC-1). To determine the origin of both polypeptides, a series of
5' truncation mutants of pHIC-1 was generated. These experiments (Fig.
3) demonstrated that p32 translation initiation was located between
position 393 and 617 (compare the lanes pHIC-3 and
pHIC-5) suggesting that ATG at position 591 could be an
initiation codon. To confirm this hypothesis, the entire region 5' to
this ATG was deleted. SDS-PAGE of the translation products synthesized
from this template revealed one major protein of 32 kDa (lane pHIC-4)
indicating that the first ATG effectively is the initiation codon
involved in p32 synthesis.
On the other hand, from the template pHIC-3, p40 was no longer
synthesized, whereas it was still produced from pHIC-2 (Fig. 3a). This observation suggests that the HIC cDNA clone
contains another initiation site upstream of the first ATG, located
between positions 174 and 393. There are many examples of proteins
where codons other than ATG are initiation codons (44-46). In human
cells, TTG and CTG have been found as initiation codons. To determine whether one or both CTG located upstream of the ATG (Fig.
3b) could be translational initiator, templates starting at
positions 246 or 321, where CTG was transformed into ATG (respectively, pHIC-I-atg and pHIC-III-atg), were constructed. Only the ATG which starts at position 246 generated a 40-kDa major product that could correspond to p40 (Fig. 3a, lane pHIC-I-atg). However, when
the CTG at position 246 was mutated into a non-initiation codon (CGG), p40 was still synthesized (Fig. 3a, lane pHIC-I-cgg). Based
on these results, it appears that both CTGs are not initiation codons and that the initiation codon must be contained within the nucleotide region between position 246 and 321. In this region, only the GTG
located at position 264 belongs to the non-ATG codons known to be able
to initiate translation in mammalian cells. For this reason, this GTG
was mutated into ATG or CGG corresponding, respectively, to the
plasmids pHIC-II-atg and pHIC-II-cgg (Fig. 3b). From
pHIC-II-atg a 40-kDa protein was produced, whereas the synthesis of
this product was abolished with pHIC-II-cgg (Fig. 3a). This
result clearly demonstrates that the GTG at position 264 is initiator
in our cell-free system.
Taken together, our data clearly demonstrate that HIC mRNA codes
for two protein isoforms, p32 and p40, synthesized from two different
initiation codons as follows: a standard ATG initiator for p32, and a
GTG located upstream of the ATG for p40. p32 and p40 only differ by the
presence of a N-terminal sequence containing two basic subdomains (Fig.
4a). Moreover, their common
C-terminal region shares 77% identical amino acids with the specific
C-terminal domain of I-mfa (Fig. 4b).
Localization of HIC p32 and p40 in Vivo--
Next we investigated
the subcellular localization of both HIC protein isoforms in
vivo. COS7 cells were transfected with vectors expressing p32 or
p40 tagged with green fluorescent protein (GFP), fused either to their
N-terminal end or their C-terminal end. As shown in Fig.
5, the position of the GFP tag apparently
has no influence on the localization of the HIC proteins. p32 is
distributed primarily throughout the cytoplasm, although weak staining
is detectable in the nucleus (Fig. 5, a and c).
Two different cytoplasmic patterns of p32 localization are observed, a
diffuse (Fig. 5, a and c) and a bright punctate
staining (Fig. 5, b and d). p40 also exhibits a
granular distribution in the cytoplasm, but in addition, it shows a
staining pattern in the nucleus, localized around and in the nucleoli
(Fig. 5, e and f).
To be certain that the GFP tag did not influence their localization,
p32 and p40 were fused to a smaller tag, containing either the
myc epitope fused to their C-terminal end (Fig.
6) or the X-press leader peptide fused to
their N-terminal end (data not shown). In COS7 cells transfected with
these constructs, p32 and p40 give the same staining pattern as that
observed with the GFP tag (compare Fig. 5 and 6). In conclusion, p32 is
predominantly cytoplasmic, whereas p40 is both cytoplasmic and nuclear.
Moreover, p32 is distributed in both a diffuse and a punctate staining
pattern throughout the cytoplasm. We do not know why two different
patterns are observed with p32. However, preliminary
data2 suggest that the
I-mfa-like domain of HIC could be involved in the formation of these
cytoplasmic granular structures.
Expression of HIC p32 and p40 in Vivo--
To raise polyclonal
antibodies against HIC, rabbits were immunized with highly purified HIC
polypeptide corresponding to the first 163 amino acids of p32. We
studied the expression of HIC protein isoforms in vivo with
this antiserum by using two additional approaches. First, we analyzed
by Western blotting (Fig. 7a)
protein extracts of 293T cells transfected with the eukaryotic
expression vector pcDNA3.1(
p40 was not detected by both approaches suggesting that p40 is weakly
expressed in vivo, probably because GTG is a poor
translation initiator. To check the existence of p40 in
vivo, the HIC coding sequence under the control of the wild type
leader (from nucleotide 95 to 1328, see Fig. 2) was cloned into the
vector pEGFP-N1, in frame with the GFP nucleotide sequence. If both HIC
isoforms are expressed in vivo, the products synthesized
from our construct should correspond to p40- and p32-GFP fusion
proteins, easily detectable by fluorescence microscopy. Indeed, after
transfection of COS7 cells, different patterns of staining were
observed with a confocal microscope. At first, a diffuse cytoplasmic
staining (Fig. 8a) was
detected confirming that p32 is expressed in vivo from HIC
cDNA. We also found a granular staining in the cytoplasm (Fig. 8,
a-c), a pattern common to p32-GFP and p40-GFP (see Fig. 5,
d and f). Finally, staining around and in the
nucleoli (Fig. 8c), similar to the pattern described for
p40-GFP (Fig. 5f), was observed. In conclusion, taken
together, our analyses demonstrate that both p32 and p40 can be
synthesized in vivo.
HIC p32 and p40 Show Opposite Effects on HTLV-I and HIV-1
LTRs--
Our results suggest that HIC protein belongs with I-mfa to
the same family of proteins that is characterized by the presence of a
specific cysteine-rich C-terminal domain. Therefore, by analogy with
I-mfa, we postulated that HIC should be involved in gene expression
regulation. Moreover, we first isolated the HIC cDNA clone from a
cDNA library of MT-2, a T-cell line persistently infected by HTLV-I
and producing high quantity of viral particles (47). For all these
reasons and in order to try to understand the function of HIC, we
investigated whether HIC was able to regulate the expression of HTLV-I
LTR. For this purpose, transient cotransfection assays were carried out
using a luciferase reporter gene driven by the HTLV-I promoter. The
transfection assays were performed in CEM cells in the presence or
absence of Tax. Although Tax alone was found to activate the expression
of luciferase reporter gene by about 20-fold as expected, luciferase
activity was over-stimulated in the presence of p32 and p40, by 50- and
60-fold, respectively (Fig. 9). This
effect is comparable to the stimulations that have been described for
cellular factors such as CREB, CREB-2, Ets1, and TBP known to cooperate
with Tax for activating transcription from the HTLV-I LTR (20, 26, 29,
48).
By analogy with I-mfa, we postulated that the I-mfa-like domain of HIC
could be involved in this regulation. To find out if this was indeed
the case we constructed a mutated HIC p40 (HIC In this report, we describe the cloning of a 4,152-bp full-length
human cDNA encoding a novel protein designated HIC. Comparison of
the nucleotide sequence of HIC cDNA with all the sequences of EMBL
and GenBankTM data bases reveals significant homologies
between the C-terminal amino acids of HIC protein and the specific
C-terminal domain of I-mfa, a cellular factor known to inhibit the
transcriptional activity of MyoD family members and Mash2
(38, 39). By in vitro translation, we demonstrated that the
HIC cDNA directed the expression of two different proteins, p32 and
p40. These two protein isoforms are synthesized from two initiation
sites of translation present in the corresponding mRNA.
Site-directed mutagenesis indicates that p32 is generated from the ATG
codon at position 591 and that p40 is an N-terminal extension of p32
produced by alternative translation initiation at an upstream GTG
codon. Although ATG is essentially used as initiation codon for
eukaryotic mRNAs, there are several examples of cellular mRNAs
where non-ATG codons located upstream of an ATG codon are also used as
initiator for the synthesis of protein isoforms. For instance, these
include proto-oncogenes such as c-myc, int-2, and
pim-1 (49-51), as well as the genes encoding the fibroblast
growth factors (52, 53), the Wilms' tumor suppressor (54), and the
high affinity neurotensin receptor (55). However, in human cells,
whereas TTG and CTG have often been found as initiation codons, GTG has
rarely been described as initiator (56-58). Non-ATG start codons can
be used to create a functionally distinct form of the same protein.
Sometimes, extended proteins show intracellular localizations different
from their shorter counterparts (50, 59). For HIC protein, p32 is
mainly distributed throughout the cytoplasm, whereas p40 is targeted to
the nucleus. This observation can be explained by the presence in HIC
p40 of an N-terminal extension containing two clusters of basic amino
acids that could direct nuclear import (60).
Despite their different intracellular localization, p32 and p40 have
similar effects on the regulation of HTLV-I and HIV-1 expression.
Indeed, we found that both HIC protein isoforms were able to stimulate
the expression of a luciferase reporter gene driven by the HTLV-I LTR
promoter in the presence of Tax but down-regulated expression from
HIV-1 LTR promoter in the presence of Tat. However, the molecular
mechanism involved in this regulation remains unclear. The effect of
HIC on Tax is obviously indirect since HIC is unable to interact
directly with Tax (data not shown). Besides, we have observed that
I-mfa is also capable of stimulating the HTLV-I transcription in the
presence of Tax,2 suggesting that the C-terminal
cysteine-rich domain, common to both proteins, is involved in this
regulation. Abolishment of HIC activity by deleting its I-mfa-like
domain confirms this hypothesis. The I-mfa-specific cysteine-rich
domain is required for binding to some bHLH factors (38). This
interaction masks the nuclear localization signal of the
transcriptional factor and thus retains the bHLH in the cytoplasm. It
is unlikely that such a similar mechanism is involved in retroviral
promoter regulation by HIC in T-cells. The bHLH proteins have not been
described as regulators of the HIV-1 and HTLV-I transcription. On the
other hand, Tax is known to repress the activity of bHLH factors
(61-63), probably through competition for common transcriptional
regulators as described recently for another transcriptional factor,
c-Myb. Tax antagonizes the c-Myb transcriptional activity by competing
for CBP (64). In our model system, HIC protein could stimulate the
transcription of the HTLV-I LTR promoter by preventing the interaction
of bHLH proteins with transcriptional regulators such as CBP which, in turn, would bind to Tax. This hypothesis could also explain why HIC
protein is able to stimulate Tat activity when this viral factor is
positioned on the HIV-1 LTR promoter since Tat is also known to recruit
transcriptional regulators to the viral promoter (65-67). On the other
hand, the down-regulating effect of HIC on Tat unbound to the viral
promoter still remains unclear. A direct interaction between HIC and
Tat could be involved in such a negative effect on Tat especially since
both proteins localize to the nucleolus (68). Experiments are under way
to evaluate further this possibility.
Another intriguing question is the putative involvement of CD4 in the
control of HIC activity. Indeed, we have previously reported that
monoclonal antibodies directed against the Ig CDR3-like region in the
extracellular domain 1 of CD4 can inhibit HIV-1 transcription in the
MT-2 T-cell line superinfected by this virus, by inducing signals that
repress NF- Our results suggest that p32 is the main isoform of HIC protein in
HTLV-I-infected T-cells. p32 presents many similarities with I-mfa as
follows: (i) their translation is initiated at an ATG codon, (ii) their
C-terminal region shares 77% identical amino acids, (iii) p32 and
I-mfa have the same size, 246 amino acids in length, (iv) both p32 and
I-mfa are mainly located in the cytoplasm, (v) p32 and I-mfa are
involved in gene expression regulation, and (vi) their C-terminal
domain is indispensable to this function. On the other hand, p40 seems
to be weakly expressed in HTLV-I-infected T-cells. However, several
observations suggest that p40 could also play a major role in
vivo. At first, the 5' structure of HIC mRNA is completely
different from that of I-mfa mRNA. Whereas the ATG initiation codon
of I-mfa cDNA is located at position 150, the ATG initiator of p32
is located at position 591 of HIC cDNA. Such a very long leader is
rare for eukaryotic mRNAs and suggests that the regulation of HIC
protein expression in vivo is more complex than that of
I-mfa. Second, preliminary data2 indicate that the
N-terminal domain of p40 is involved in the import of HIC in the
nucleus, showing that this domain has an essential function in
vivo. Finally, p40 is more efficient than p32 in regulating the
expression of a luciferase gene driven by the HTLV-I or HIV-1 LTR.
In conclusion, we propose that HIC and I-mfa represent two members of a
new family of gene expression regulators, characterized by a particular
cysteine-rich C-terminal domain. Our study opens a new perspective in
understanding the role of these new factors in the pathology of
diseases such as AIDS and T-cell leukemia.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
gt11 were purchased from CLONTECH.
RNA hybridization and library screening were performed as described by
the manufacturer. The HIC cDNA encompassing the nucleotides from
position 1148 to 1639 was labeled with [
-32P]dCTP
using the method of random priming and was used as a probe.
)/Myc-His (Invitrogen). We also cloned an NheI-KpnI
fragment of HIC cDNA (from position 95 to 1328) into pEGFP-N1 to
analyze the production of HIC protein isoforms in vivo from
the wild type leader. COS7 cells were transfected using the calcium
phosphate-mediated transfection method with 20 µg of expression
vector. Cells were cultivated on the glass slides and then analyzed by
fluorescence 24 h after transfection. p32 and p40 tagged with the
myc epitope were detected by using the anti-myc
monoclonal antibody purchased from Sigma and goat anti-mouse
immunoglobin G antibody coupled to fluorescein isothiocyanate. Analysis
of the green, red, and yellow fluorescence was performed with a Bio-Rad
MRC 1024 confocal microscope.
,
which contains the entire coding sequence of p40 except for the
I-mfa-like domain, was constructed by digesting p40 cDNA cloned
into pcDNA3.1/His with EcoRV and XhoI. The
resulting digest was treated with Klenow and religated as blunt ends.
This approach resulted in the deletion of the last 101 amino acids. The
Tat and Tax expression vectors, pBg312HIV-1Lai-Tat and pSG-Tax, respectively, have been described previously (40, 41). CEM cells were
transiently cotransfected according to the procedure published
previously (42). 5 µg of pAC
1 (
-galactosidase-containing reference plasmid) was included in each transfection for controlling the transfection efficiency. The total amount of DNA in each
transfection was the same, the balance being made up with empty
pcDNA3.1/His. Cell extracts equalized for protein content were used
for luciferase and
-galactosidase assays. For the assays with the
GAL4-binding site promoter-reporter plasmid, HIC (amino acids 120 to
355), Tax, and Tat were fused in frame with the DNA-binding domain of GAL4 (cloned into pBIND vector, Promega). Cotransfection assays were
performed in CEM cells in the presence of the luciferase reporter
plasmid pG5luc containing five GAL4-binding sites upstream of a minimal
TATA box.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
gt11 to characterize the
complete sequence of HIC cDNA. By this approach, we were able to
isolate a 4,152-bp full-length HIC cDNA that was completely
sequenced (GenBankTM number AF054589).

View larger version (56K):
[in a new window]
Fig. 1.
Tissue distribution of HIC mRNA.
Northern blot of poly(A)+ RNA from various human tissues
was analyzed. Molecular size markers in kilobases (kb) are
shown on the left.

View larger version (54K):
[in a new window]
Fig. 2.
The 5' end nucleotide and deduced amino acid
sequences of the full-length HIC cDNA isolated from a human spleen
cDNA library. The amino acid sequence deduced from the longest
open reading frame is shown below the nucleotides. The
sequence data of the complete HIC cDNA have been submitted to the
GenBankTM data base under accession number AF054589.

View larger version (61K):
[in a new window]
Fig. 3.
Mapping of the translation initiation sites
of the HIC cDNA clone with a cell-free system. a, all
mRNAs were translated in rabbit reticulocyte lysates with either an
HIC cDNA clone containing the first 1532 bp or PCR-generated DNAs
as templates for transcription. [35S]Methionine and
[35S]cysteine were used in translation reactions to label
proteins. Translation products were analyzed by SDS-PAGE and
autoradiography. 35S-Labeled p40 and p32 are designated by
arrows. Molecular size markers in kilodaltons are shown on
the right. The exact start of the different HIC constructs
are shown in b below the autoradiographs.
b, nucleic acid sequence of the 5' end of the HIC cDNA
clone. The stop codon TAG at position 171 and the putative initiation
codons are indicated in bold. The exact position of the 5'
end of the different HIC cDNA clones is indicated by an
arrow. pHIC-1 and the 5' deleted plasmids, pHIC-2, -3, -4, and -5, encode the wild type nucleotide sequence of HIC cDNA. For
the other deleted constructs, the 5' end was modified as follows: CTG
at position 246 was transformed into ATG (pHIC-I-atg) or CGG
(pHIC-I-cgg), GTG at position 264 into ATG (pHIC-II-atg) or CGG
(pHIC-II-cgg), and CTG at position 321 into ATG (pHIC-III-atg).

View larger version (43K):
[in a new window]
Fig. 4.
The amino acid sequence of HIC p32 and p40.
a, the complete amino acid sequence corresponds to HIC p40.
Underlined amino acids delineate both basic rich subdomains
of p40. The first methionine of p32 corresponding to initiation codon
is indicated in bold. b, the C-terminal 82 amino
acids of HIC protein aligned with the specific C-terminal domain of
I-mfa. Identical residues are boxed.

View larger version (19K):
[in a new window]
Fig. 5.
Confocal microscopy analysis of the
subcellular localization of HIC p32 and p40 with an N- or C-terminal
GFP tag in vivo. COS7 cells were transfected with
20 µg each of expression vector encoding GFP-p32 (a and
b), p32-GFP (c and d), GFP-p40
(e), or p40-GFP (f). Cells were cultivated on the
glass slides and then analyzed by fluorescence 24 h after
transfection. Analysis of the green, red, and
yellow fluorescence was performed with confocal microscope.
The yellow color results from the merging of the green
fluorescence of GFP-tagged proteins and red staining (propidium iodide)
of the cell nucleus.

View larger version (25K):
[in a new window]
Fig. 6.
Confocal microscopy analysis of the
subcellular localization of HIC p32 and p40 with a C-terminal
myc tag in vivo. COS7 cells were
transfected with 20 µg of pcDNA3.1(
)/Myc-His expressing p32
(a and b) or p40 (c) fused to the
myc epitope. Microscopy analysis was performed as described
in the legend of Fig. 5.
)/Myc-His containing the HIC coding
sequence under the control of the wild type leader (from nucleotide 95 to 1300, see Fig. 2). Second, we performed immunoprecipitation with
anti-HIC from extracts of HTLV-I infected T-cells (Fig. 7b). In both cases, a single protein was detected with anti-HIC but not with
preimmune serum (Fig. 7), the size of this protein being consistent
with the size of recombinant p32 when expressed in eukaryotic cell
lines (data not shown). These results demonstrate that p32 is the major
protein isoform produced from HIC mRNA in vivo.

View larger version (27K):
[in a new window]
Fig. 7.
Detection of p32 in vivo by
Western blot (a) or by immunoprecipitation
(b). a, 100 µg of total protein extracts
were analyzed by SDS-PAGE and immunoblotting using control serum
obtained from an uninjected rabbit (lanes 1 and
2) or anti-HIC serum (lanes 3 and 4).
Protein extracts were prepared from 293T cells transfected with
empty pcDNA3.1(
)/Myc-His (lanes 1 and
3) or with pcDNA3.1(
)/Myc-His containing the HIC
coding sequence under the control of the wild type leader (lanes
2 and 4). b, HIC p32 was immunoprecipitated
from MT-2 cell lysate (20 × 106 cells) using control
serum (lane 1) or anti-HIC serum (lane 2) and
protein A-Sepharose. Precipitates were analyzed by SDS-PAGE and
immunoblotting with anti-HIC serum. The predicted positions of p40 and
p32 are designated by arrows on the right of the
immunoblots.

View larger version (10K):
[in a new window]
Fig. 8.
Analysis of HIC expression in vivo
from the wild type HIC cDNA by confocal microscopy. COS7
cells were transfected with pEGFP-N1 containing GFP nucleotide sequence
in frame with the HIC coding sequence under the control of the wild
type leader. Analysis of transfected cells was carried out as described
in the legend of the Fig. 5. The three different patterns, which have
been observed, are shown in a-c.

View larger version (22K):
[in a new window]
Fig. 9.
Stimulation of HTLV-I LTR by HIC p32 and
p40. CEM cells were cotransfected with 2 µg of HTLV-I
LTR-luciferase, 5 µg of pAC
1 (
-galactosidase-containing
reference plasmid), 1 µg of Tax expression vector pSG-Tax or empty
pSG-5 vector, and 0, 2, or 10 µg of pcDNA3.1/His expressing p32
or p40. Luciferase values were normalized for
-galactosidase
activity and are expressed as fold increase relative to that of cells
transfected with 2 µg of HTLV-I LTR-luciferase, 5 µg of pAC
1, 1 µg of pSG-5, and 10 µg of empty pcDNA3.1/His. Values are the
means ± S.D. (n = 3).
) deleted of its
C-terminal domain. HIC
has a removal of the last 101 amino acid
residues encompassing the I-mfa-like domain (see Fig. 4). No
over-stimulation of the luciferase gene expression from the HTLV-I LTR
was detected with this mutant, although it was stably expressed in
transfected cells (Fig. 10). This
result confirms that the stimulation of luciferase expression from
HTLV-I LTR by the wild type HIC, in the presence of Tax, is
significant. Finally, to determine whether the stimulation was specific
to HTLV-I, the effects of HIC were also tested on two other viral activators, the herpes simplex virus transactivator VP16 and the HIV-1
Tat protein. Whereas HIC has no effect on the VP16 activity (data not
shown), the results obtained with Tat were unexpected. In the presence
of HIC, the activation by Tat from HIV-1 LTR was down-regulated,
especially with p40 (Fig.
11a). Such an effect was not
detected in the presence of HIC
(Fig. 11b). Taken
together, our results suggest that HIC is able to modulate the
expression of the HTLV-I and HIV-1 genomes, and its I-mfa-like domain
is involved in this effect. To define better the function of this domain, we constructed a GAL4-HIC fusion protein in which the GAL4
DNA-binding domain was linked in frame to HIC (amino acids 120-355;
see Fig. 4a). GAL4-HIC was assayed by using the luciferase reporter vector pG5luc, which contains five GAL4-binding sites upstream
of a minimal TATA box. We found that GAL4-HIC was unable to stimulate
the luciferase expression (Fig.
12a); this result suggests
that HIC has no transcriptional activation domain. On the other hand,
the GAL4-Tax and GAL4-Tat activities were stimulated 4.5- and 3-fold,
respectively, in the presence of HIC (Fig. 12). Thus, HIC has the same
activator effect on both Tax and Tat when these viral factors are
positioned on the promoter.

View larger version (17K):
[in a new window]
Fig. 10.
The I-mfa-like domain of HIC is involved in
the stimulation of the HTLV-I LTR expression. a, CEM cells
were cotransfected with 2 µg of HTLV-I LTR-luciferase, 5 µg of
pAC
1, 1 µg of pSG-Tax or empty pSG-5, and 10 µg of empty
pcDNA3.1/His or 10 µg of pcDNA3.1/His expressing HIC p40 or
HIC
. Values are the means ± S.D. (n = 3).
b, expression of the wild type and mutated HIC proteins in
cotransfected CEM cells was checked by Western blotting by using the
anti-Xpress serum:
, cells cotransfected with empty pcDNA3.1/His;
p40, cells cotransfected with pcDNA3.1/His expressing
HIC p40; HIC
, cells cotransfected with pcDNA3.1/His
expressing HIC
.

View larger version (14K):
[in a new window]
Fig. 11.
Down-regulation of HIV-1 LTR by HIC p32 and
p40. To test the effects of HIC p32 and p40 (a) and
HIC
(b) on the HIV-1 LTR-luciferase, CEM cells were
transfected as described in the legends of Fig. 9 and 10, but with
HIV-1 LTR and Tat expression vector instead of HTLV-I LTR and pSG-Tax.
Values are the means ± S.D. (n = 3).

View larger version (9K):
[in a new window]
Fig. 12.
Stimulation of GAL4-Tax and GAL4-Tat
activities by HIC. a, CEM cells were cotransfected with 2 µg of the luciferase reporter vector pG5luc, 5 µg of pAC
1, and 2 µg of a eukaryotic vector expressing a GAL4-HIC fusion protein. The
GAL4-Tax activity was also tested with pG5luc in the presence of 10 µg of empty pcDNA3.1/His or 10 µg of pcDNA3.1/His
expressing HIC p40. Luciferase values were normalized for
-galactosidase activity and are expressed as fold increase relative
to that of cells transfected with 2 µg of pG5luc, 5 µg of pAC
1,
and 12 µg of empty pcDNA3.1/His. Values are the means ± S.D. (n = 3). b, the same experiments were
also performed with GAL4-Tat.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B activation (43, 69). We have established that the
transcription of the lck gene, which encodes a cytoplasmic
CD4-associated kinase linking CD4 to signal transduction cascade, is
repressed in MT-2 cells (43, 69). This result suggests that inhibition
of HIV-1 transcription in these cells is a consequence of signal
transduction probably mediated by an unidentified factor capable of
associating with CD4. It is noteworthy that several reports demonstrate
that some CD4 signals do not require Lck thereby suggesting the
involvement of unknown molecules (70-72). In trying to identify this
factor by the yeast two-hybrid approach by using the CD4 cytoplasmic
tail as a bait, we isolated two cDNA clones encoding the C-terminal
domain of HIC. We have also found by two-hybrid assay that HIC binds
more efficiently to the wild type CD4 cytoplasmic tail than to a mutant form with cysteine mutations in its cytoplasmic fragment, suggesting that cysteines of HIC and CD4 are likely involved in the
protein-protein interaction.3
Interestingly, HIC is capable of down-regulating HIV-1 transcription. However, confocal microscopy analyses do not argue in favor of CD4/HIC
cellular colocalization. Moreover, we also failed to
coimmunoprecipitate HIC and CD4 from cotransfected cells. For these
reasons, we cannot presently claim that the interaction between HIC and
CD4 really occurs in MT-2 cells. Yet, we can expect that further
characterization of exact mechanisms involved in the regulation of
HTLV-I and HIV-1 LTR expression by HIC may contribute to answer this question.
| |
ACKNOWLEDGEMENTS |
|---|
We thank the Comité de l'Hérault de la Ligue Contre le Cancer for the financing of the production of the anti-HIC serum. We thank P. Jalinot for the Tax expression vector, I. Hirsch for the Tat expression vector, and J. Nyborg for HTLV-I LTR luciferase reporter plasmid. Confocal microscopy was performed by the Service de Cytométrie at the Center Régional d'Imagerie Cellulaire (CRIC) in Montpellier.
| |
FOOTNOTES |
|---|
* This work was supported in part by institutional grants from the CNRS and by Association pour la Recherche sur le Cancer Grant 6238.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF054589.
§ Fellow of the CNRS (Bourse Docteur Ingénieur).
¶ Fellow of the Ministère de l'Education Nationale de la Recherche et de la Technologie (MENRT).
Present address: Dept. of Biochemistry and Molecular Biology,
Colorado State University, Fort Collins, CO 80523-1870.
** To whom correspondence should be addressed: Laboratoire Infections Rétrovirales et Signalisation Cellulaire, Institut de Biologie, 4 Bd. Henri IV, 34060 Montpellier, France. Tel.: (33) 4 67 60 86 60; Fax: (33) 4 67 60 44 20; E-mail: mesnard@crbm.cnrs-mop.fr.
2 S. Thébault, unpublished results.
3 N. Coudronnière and J.-M. Mesnard, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: HTLV-I, human T-cell leukemia virus type I; HIV-1, human immunodeficiency virus type 1; bp, base pair; LTR, long terminal repeat; CREB, CRE-binding proteins; CBP, CREB-binding protein; bHLH, basic helix-loop-helix; PAGE, polyacrylamide gel electrophoresis; GFP, green fluorescent protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Chun, R. F.,
and Jeang, K.-T.
(1996)
J. Biol. Chem.
271,
27888-27894 |
| 2. |
Mavankal, G.,
Ignatius Ou, S. H.,
Oliver, H.,
Sigman, D.,
and Gaynor, R. B.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2089-2094 |
| 3. |
Okamoto, H.,
Sheline, C. T.,
Corden, J. L.,
Jones, K. A.,
and Peterlin, B. M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
11575-11579 |
| 4. | Parada, C. A., and Roeder, R. G. (1996) Nature 384, 375-378[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Arya, S. K.,
Guo, C.,
Josephs, S. F.,
and Wong-Staal, F.
(1985)
Science
229,
69-73 |
| 6. |
Sodroski, J. G.,
Patarca, R.,
Rosen, C. A.,
Wong-Staal, F.,
and Haseltine, W. A.
(1985)
Science
229,
74-75 |
| 7. | Cullen, B. (1986) Cell 46, 973-982[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Berkhout, B., Silverman, R. H., and Jeang, K. T. (1989) Cell 59, 273-282[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Dingwall, C., Ernberg, I., Gait, M. J., Green, S. M., Heaphy, S., Karn, J., Lowe, A. D., Singh, M., and Skinner, M. A. (1990) EMBO J. 9, 4145-4153[Medline] [Order article via Infotrieve] |
| 10. |
Weeks, K. M.,
Ampe, C.,
Schultz, S. C.,
Steitz, T. A.,
and Crothers, D. M.
(1990)
Science
249,
1281-1285 |
| 11. |
Jones, K. A.
(1997)
Genes Dev.
11,
2593-2599 |
| 12. | Cullen, B. R. (1998) Cell 93, 685-692[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Jeang, K. T.,
Boros, I.,
Brady, J.,
Radanovich, M.,
and Khoury, G.
(1988)
J. Virol.
62,
4499-4509 |
| 14. | Beimling, P., and Moelling, K. (1989) Oncogene 4, 511-516[Medline] [Order article via Infotrieve] |
| 15. |
Giam, C.-Z.,
and Xu, Y.-L.
(1989)
J. Biol. Chem.
264,
15236-15241 |
| 16. |
Suzuki, T.,
Fujisawa, J. I.,
Toita, M.,
and Yoshida, M.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
610-614 |
| 17. | Yin, M.-J., Paulssen, E. J., Seeler, J.-S., and Gaynor, R. B. (1995) J. Virol. 69, 3420-3432[Abstract] |
| 18. | Bantignies, F., Rousset, R., Desbois, C., and Jalinot, P. (1996) Mol. Cell. Biol. 16, 2174-2182[Abstract] |
| 19. | Reddy, T. R., Tang, H., Li, X., and Wong-Staal, F. (1997) Oncogene 14, 2785-2792[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Gachon, F.,
Péléraux, A.,
Thébault, S.,
Dick, J.,
Lemasson, I.,
Devaux, C.,
and Mesnard, J. M.
(1998)
J. Virol.
72,
8332-8337 |
| 21. |
Fujisawa, J. I.,
Seiki, M.,
Kiyokawa, T.,
and Yoshida, M.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
2277-2281 |
| 22. |
Paskalis, H.,
Felber, B. K.,
and Pavlakis, G. N.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
6558-6562 |
| 23. |
Shimotohno, K.,
Takano, M.,
Teruuchi, T.,
and Miwa, M.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
8112-8116 |
| 24. |
Brady, J.,
Jeang, K. T.,
Duvall, J.,
and Khoury, G.
(1987)
J. Virol.
61,
2175-2181 |
| 25. |
Rosen, C. A.,
Park, R.,
Sodroski, J. G.,
and Haseltine, W. A.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
4919-4923 |
| 26. | Kwok, R. P. S., Laurance, M. E., Lundblad, J. R., Goldman, P. S., Shih, H.-M., Connor, L. M., Marriott, S. J., and Goodman, R. H. (1996) Nature 370, 223-226 |
| 27. | Giebler, H. A., Loring, J. E., Van Orden, K., Colgin, M. A., Garrus, J. E., Escudero, K. W., Brauweiler, A., and Nyborg, J. K. (1997) Mol. Cell. Biol. 17, 5156-5164[Abstract] |
| 28. |
Bex, F.,
Yin, M. J.,
Burny, A.,
and Gaynor, R. B.
(1998)
Mol. Cell. Biol.
18,
2392-2405 |
| 29. | Caron, C., Rousset, R., Béraud, C., Moncollin, V., Egly, J.-M., and Jalinot, P. (1993) EMBO J. 12, 4269-4278[Medline] [Order article via Infotrieve] |
| 30. | Clemens, K. E., Piras, G., Radonovich, M. F., Choi, K. S., Duvall, J. F., DeJong, J., Roeder, R., and Brady, J. N. (1996) Mol. Cell. Biol. 16, 4656-4664[Abstract] |
| 31. |
Caron, C.,
Mengus, G.,
Dubrowskaya, V.,
Roisin, A.,
Davidson, I.,
and Jalinot, P.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3662-3667 |
| 32. | Jan, Y. N., and Jan, L. Y. (1993) Cell 75, 827-830[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Weintraub, H. (1993) Cell 75, 1241-1244[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Rudnicki, M. A., and Jaenisch, R. (1995) BioEssays 17, 203-209[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Guillemot, F., Nagy, A., Auerbach, A., Rossant, J., and Joyner, A. L. (1994) Nature 371, 333-336[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Firulli, A. B., McFadden, D. G., Lin, Q., Srivastava, D., and Olson, E. N. (1998) Nat. Genet. 18, 266-270[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Riley, P., Anson-Cartwright, L., and Cross, J. C. (1998) Nat. Genet. 18, 271-275[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Chen, C.-M. A., Kraut, N., Groudine, M., and Weintraub, H. (1996) Cell 86, 731-741[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Kraut, N., Snider, L., Chen, C.-M. A., Tapscott, S. J., and Groudine, M. (1998) EMBO J. 17, 6276-6288[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Hirsch, I., Spire, B., Tsunetsugu-Yokota, Y., Neuveut, C., Sire, J., and Chermann, J. C. (1990) Virology 177, 759-763[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Rousset, R., Desbois, C., Bantignies, F., and Jalinot, P. (1996) Nature 381, 328-331[CrossRef][Medline] [Order article via Infotrieve] |
| 42. |
Lemasson, I.,
Thébault, S.,
Sardet, C.,
Devaux, C.,
and Mesnard, J. M.
(1998)
J. Biol. Chem.
273,
23598-23604 |
| 43. | Coudronnière, N., Corbeil, J., Robert-Hebmann, V., Mesnard, J.-M., and Devaux, C. (1998) Eur. J. Immunol. 28, 1445-1457[CrossRef][Medline] [Order article via Infotrieve] |
| 44. |
Kozak, M.
(1991)
J. Biol. Chem.
266,
19867-19870 |
| 45. | Boeck, R., and Kolakofsky, D. (1994) EMBO J. 13, 3608-3617[Medline] [Order article via Infotrieve] |
| 46. |
Drabkin, H. J.,
and Rajbhandary, U. L.
(1998)
Mol. Cell. Biol.
18,
5140-5147 |
| 47. | Miyoshi, I., Taguchi, H., Kubonishi, I., Yoshimoto, S., Ohtsuki, Y., Shiraishi, Y., and Akagi, T. (1982) Gann 28, 219-228 |
| 48. |
Gitlin, S. D.,
Dittmer, J.,
Shin, R. C.,
and Brady, J. N.
(1993)
J. Virol.
67,
7307-7316 |
| 49. | Hann, S. R., King, M. W., Bentley, D. L., Anderson, C. W., and Eisenman, R. N. (1988) Cell 52, 185-195[CrossRef][Medline] [Order article via Infotrieve] |
| 50. | Acland, P., Dixon, M., Peters, G., and Dickson, C. (1990) Nature 343, 662-665[CrossRef][Medline] [Order article via Infotrieve] |
| 51. | Saris, C. J., Domen, J., and Berns, A. (1991) EMBO J. 10, 655-664[Medline] [Order article via Infotrieve] |
| 52. |
Prats, H.,
Kaghad, M.,
Prats, A. C.,
Klagsbrun, M.,
Lelias, J. M.,
Liauzun, P.,
Chalon, P.,
Tauber, J. P.,
Amalric, F. S.,
Smith, J. A.,
and Caput, D.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1836-1840 |
| 53. |
Arnaud, E.,
Touriol, C.,
Boutonnet, C.,
Gensac, M. C.,
Vagner, S.,
Prats, H.,
and Prats, A. C.
(1999)
Mol. Cell. Biol.
19,
505-514 |
| 54. |
Bruening, W.,
and Pelletier, J.
(1996)
J. Biol. Chem.
271,
8646-8654 |
| 55. | Botto, J. M., Vincent, J. P., and Mazella, J. (1997) Biochem. J. 324, 389-393 |
| 56. |
Boeck, R.,
Curran, J.,
Matsuoka, Y.,
Compans, R.,
and Kolakofsky, D.
(1992)
J. Virol.
66,
1765-1768 |
| 57. | Davidson, L., Golovoy, N., and Roessler, B. J. (1994) Hum. Genet. 93, 300-304[CrossRef][Medline] [Order article via Infotrieve] |
| 58. | Imataka, H., Olsen, H. S., and Sonenberg, N. (1997) EMBO J. 16, 817-825[CrossRef][Medline] [Order article via Infotrieve] |
| 59. |
Bugler, B.,
Amalric, F.,
and Prats, H.
(1991)
Mol. Cell. Biol.
11,
573-577 |
| 60. | Mattaj, I. W., and Englmeier, L. (1998) Annu. Rev. Biochem. 67, 265-306[CrossRef][Medline] [Order article via Infotrieve] |
| 61. |
Uittenbogaard, M. N.,
Armstrong, A. P.,
Chiaramello, A.,
and Nyborg, J. K.
(1994)
J. Biol. Chem.
269,
22466-22469 |
| 62. |
Semmes, O. J.,
Barret, J. F.,
Dang, C. V.,
and Jeang, K.-T.
(1996)
J. Biol. Chem.
271,
9730-9738 |
| 63. | Lemasson, I., Robert-Hebmann, V., Hamaia, S., Duc Dodon, M., Gazzolo, L., and Devaux, C. (1997) J. Virol. 71, 1975-1983[Abstract] |
| 64. |
Colgin, M. A.,
and Nyborg, J. K.
(1998)
J. Virol.
72,
9396-9399 |
| 65. |
Benkirane, M.,
Chun, R. F.,
Xiao, H.,
Ogryzko, V. V.,
Howard, B. H.,
Nakatani, Y.,
and Jeang, K.-T.
(1998)
J. Biol. Chem.
273,
24898-24905 |
| 66. |
Hottiger, M. O.,
and Nabel, G. J.
(1998)
J. Virol.
72,
8252-8256 |
| 67. |
Marzio, G.,
Tyagi, M.,
Gutierrez, M. I.,
and Giacca, M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13519-13524 |
| 68. |
Hauber, J.,
Malim, M. H.,
and Cullen, R.
(1989)
J. Virol.
63,
1181-1187 |
| 69. | Lemasson, I., Briant, L., Hague, B., Coudronnière, N., Heron, L., David, C., Rebouissou, C., Kindt, T., and Devaux, C. (1996) J. Immunol. 156, 859-865[Abstract] |
| 70. |
Zerbib, A. C.,
Reske-Kunz, A. B.,
Lock, P.,
and Sékaly, R.-P.
(1994)
J. Exp. Med.
179,
1973-1983 |
| 71. |
Gratton, S.,
Julius, M.,
and Sékaly, R.-P.
(1998)
J. Immunol.
161,
3551-3556 |
| 72. |
Bonnard, M.,
Haughn, L.,
and Julius, M.
(1999)
J. Immunol.
162,
1252-1260 |